Answers are grounded in this paper and cite their sources.
Crimean-Congo hemorrhagic fever virus (CCHFV) is a high-consequence pathogen for which no approved antivirals or vaccines exist. The viral nucleocapsid protein (N protein) is central to the Nairovirus life cycle, coordinating genomic RNA encapsidation and selective enhancement of viral mRNA translation through its interaction with the panhandle-like hairpin structure in the S-segment mRNA 5′ untranslated region (UTR). Here, we developed a robust fluorescence polarization anisotropy (FPA) based high-throughput assay capable of quantitatively monitoring the interaction between purified N protein and the viral 5′UTR hairpin. The assay demonstrated excellent stability, DMSO tolerance, and performance metrics (average Z′ > 0.6), enabling the screening of 108,947 small molecules. Primary screening identified 122 inhibitors, 86 of which showed clear dose-responsive activity. Cluster analysis, medicinal chemistry filtering, and repurchase-based validation yielded 37 confirmed hits, from which compounds 11, 14, and 33 were prioritized for further testing. Biochemical analysis demonstrated that all three compounds noncompetitively inhibit N protein–UTR binding with IC₅₀ values of 11–41 μM. These compounds exhibited minimal cytotoxicity (CC₅₀ > 1–2 mM) and potent antiviral activity in cell culture against Hazara virus (HZV), a BSL-2 surrogate for CCHFV, with EC₅₀ values of ~23–51 μM and favorable selectivity indices (>34–86). Plaque assays further showed that compounds 11 and 14 reduced the production of infectious viral particles by over 100-fold, whereas compound 33 nearly eliminated detectable infectious virus in the media. Mechanistic assays revealed that these inhibitors act during post-entry steps and selectively block the N protein–mediated enhancement of viral mRNA translation without affecting the canonical host translation machinery. Molecular modeling and biochemical/translation assays support binding of compound 11 to the N protein stalk–head interface, involving residues Gln300, Glu240 and Lys473. Collectively, these findings identify the N protein–5′UTR interface as a tractable antiviral target and establish first-in-class small-molecule inhibitors that disrupt essential Nairovirus RNA–N protein interaction. These compounds provide strong leads for further optimization and development of urgently needed therapeutics for CCHFV.
No takes yet. Share an insight, caveat, or question.
Le et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: